Tom Chivers, a science writer known for his book 'Everything is Predictable', dives into the world of statistics and its influence on everyday life. He discusses Bayes' Theorem and the complexities of developing Alzheimer's treatments, such as the new drug Lecanumab. Chivers also explores innovative agricultural techniques, like smart paint for greenhouses that enhances plant growth. Additionally, Professor Sean Tweedy explains the Paralympic classification system, highlighting how athletes are grouped for fair competition amid evolving standards.
Bayes' Theorem exemplifies the importance of updating beliefs with new evidence, especially in scenarios like medical testing.
The approval of lecanumab highlights the complexities of developing Alzheimer’s treatments and the ethical dilemmas faced in healthcare decisions.
Deep dives
Understanding Bayes' Theorem
Bayes' Theorem serves as a powerful mathematical tool for making predictions based on prior information and new data. Originating from an equation developed by Reverend Thomas Bayes in the 18th century, the theorem allows for a better understanding of probabilities in everyday situations. An example described involves assessing the likelihood of having a particular medical condition after receiving a positive test result, emphasizing that people often overlook the importance of initial probabilities. This intuitive approach to information processing reflects how humans naturally update their beliefs and predictions in light of new evidence.
Advancements in Alzheimer's Drug Development
Lecanumab has become a pivotal drug in slowing the progression of Alzheimer's disease, marking a significant milestone in a long struggle against this debilitating condition. It works by targeting and removing toxic amyloid-beta proteins from the brain, which are linked to the accumulation of damage in Alzheimer's patients. Despite its approval in the UK, challenges remain, such as monitoring for rare but serious side effects and the limited degree of progression slowing it offers. Researchers are optimistic, however, as Lecanumab's success paves the way for further innovations and funding in the field of Alzheimer's treatment.
Classifying Impairments in Paralympic Sports
The classification of athletes with disabilities in the Paralympic Games aims to create a fair competitive environment by grouping athletes with similar levels of impairment. Initially based on medical conditions, this system has evolved into functional classification, which considers athletes' training and performance. New approaches are now being explored using artificial intelligence, which can analyze performance data and provide more objective class allocations. This transition demonstrates the ongoing efforts to enhance the accuracy and fairness of competition while ensuring that athletes are not unfairly disadvantaged due to varying impairments.
Challenges and Ethical Concerns in Alzheimer's Research
The podcast highlights the ethical dilemmas and regulatory challenges surrounding new Alzheimer's treatments, particularly in light of the controversial approval process for Aducanumab. Concerns have been raised about the reliability of research data and potential conflicts that could arise in drug development, impacting patient trust and healthcare decisions. As researchers work diligently to gather robust evidence, the urgency to find effective solutions for Alzheimer's becomes increasingly critical, particularly given the emotional and financial toll on patients and families. The ongoing debate emphasizes the need for rigorous scientific practices to ensure that breakthroughs can genuinely improve patient outcomes.
The Royal Society recently announced the shortlist for their annual Science Book Prize – and nominated is science writer and journalist Tom Chivers, author of the book Everything is Predictable. He tells us how statistics impact every aspect of our lives, and joins Marnie as a studio guest throughout the show.
A drug – lecanemab – that can slow the progression of Alzheimer’s disease has recently been approved for use in the UK, but the healthcare regulator NICE has said that it won’t be available on the NHS. But what is behind this decision, and what makes creating an Alzheimer’s drug so difficult? Professor Tara Spires-Jones from the University of Edinburgh talks us through the science.
And could ‘smart paint’ supersize our fruit and veg? Reporter Roland Pease heads over to the experimental greenhouses of Cranfield University’s crop science unit to see if the technology works.
Thee Paralympic Games are now underway in Paris, with athletes competing across 22 different events. But as competitors have a range of different impairments, how is it ensured that there's a level playing field? Professor Sean Tweedy from the University of Queensland calls in from Paris to explain how athletes are sorted into categories for competition.
Presenter: Marnie Chesterton
Producers: Sophie Ormiston and Ella Hubber
Editor: Martin Smith
Production Co-ordinator: Andrew Lewis
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode